

1 **The Pattern of rpoB gene mutation of *Mycobacterium tuberculosis* and predictors of**
2 **rifampicin resistance detected by gene Xpert MTB/Rif in Tanzania.**

3 **Authors**

4 Peter Richard Torokaa^{1,2*}, Heledy Kileo³, Loveness Urio², Mariam R. Mbwana^{1,2} Mariam C.
5 Monah^{1,2}, Sefhord Saul Ntibabara^{1,2}, Jasper Kimambo^{1,2}, Paschal Seleman³, Collins Franklin³,
6 Robert Balama³, Riziki M. Kisonga³, Mtebe V. Majigo⁴, Agricola Joachim⁴

7 **Affiliations**

8 ¹Muhimbili University of Health and Allied Sciences, School of Public Health and Social Sciences,
9 Dar es Salaam, Tanzania.

10 ²Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania.

11 ³Ministry of Health, National TB and Leprosy Program, Dodoma Tanzania.

12 ⁴Muhimbili University of Health and Allied Sciences, College of Medicine, Dar es Salaam,
13 Tanzania

14 ***Corresponding Author:** Peter Torokaa, Email: peteratorokaa@gmail.com (PRT)

15 **ABSTRACT**

16 **Introduction**

17 Antimicrobial resistance associated with *Mycobacterium tuberculosis* (MTB) is the challenge
18 facing Tuberculosis (TB) management worldwide. Rifampicin resistance (RR) has been associated
19 with the rpoB gene mutation. No study was conducted in Tanzania to determine the commonest
20 mutation. The inconsistent findings from various studies support the need to determine whether

21 reported mutation patterns are applicable in our setting. We determined the frequency of rpoB gene
22 mutation and factors associated with RR detected using GeneXpert MTB/Rif.

23 **Methods**

24 We conducted a retrospective cross-sectional study involving data from the National Tuberculosis
25 and Leprosy Program database from 2020 to 2022 for cases investigated using GeneXpert.
26 Descriptive analysis was performed as the frequency for categorical variables. The chi-square test
27 and regression analysis assessed the relationship between the independent variables and outcome.
28 The 95% confidence interval and a significance level of $p < 0.05$ were used to assess the association
29 strength.

30 **Results**

31 A total of 56,004 participants had status of MTB and RR. Most, 38,705/56,004 (69.11%) were male.
32 Probe E, 89/219 (40.64%) was the predominant. Human immunodeficiency virus (HIV)-positive
33 patients had a higher gene mutation, 134/10601 (1.26%) than HIV-negative, 306/45016 (0.68%)
34 ($p < 0.001$). Patients with both pulmonary and extra-pulmonary TB had about four times greater odds
35 of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 – 8.32). RR was nearly nine times
36 higher in previously treated patients than new patients (AOR 8.66, 95%CI: 6.97–10.76). HIV-
37 positive individuals had nearly twice the odds of developing RR than HIV-negative individuals
38 (AOR 1.91, 95%CI: 1.51 – 2.42).

39 **Conclusion**

40 The rate of RR was low compared to other studies in Tanzania, with probe E mutations the most
41 prevalent. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-

42 TB had more risk of RR. The findings highlight the need to strengthen surveillance of multidrug-
43 resistant-TB among patients with a higher risk of RR.

44 **Keywords:** *Mycobacterium tuberculosis*, rifampicin resistance, GeneXpert, probe mutations,
45 Tanzania

46 **Introduction**

47 Multidrug-resistant *Mycobacterium tuberculosis* (MDR-TB) is the biggest challenge facing
48 Tuberculosis (TB) care and treatment worldwide (1). MDR-TB is a major contributor to global
49 antimicrobial resistance (AMR) and continues to pose a public health threat (1–3). MDR-TB is
50 considered when there is resistance to isoniazid and rifampicin, with or without resistance to other
51 first-line drugs. The main problem is rifampicin resistance, the most potent first-line treatment (1).
52 Patients with rifampicin-resistant TB or MDR-TB require a second-line treatment regimen (4).
53 Globally, the annual estimated number of MDR-TB or rifampicin-resistant TB cases was steady
54 between 2015 and 2020; however, it increased in 2021. In 2021, it was estimated to be 450,000
55 events, a 3.1% increase from 437,000 in 2020 (1).

56 The World Health Organization (WHO) developed a strategy to end TB-related deaths, illnesses,
57 and suffering by 2035 (5). It recommends accelerating the identification and enhancing treatment
58 for MDR-TB. Apart from access to diagnosis, adequate infection control must also be implemented
59 in the settings where patients are treated (4). To diagnose MDR-TB, WHO recommends more
60 specific and sensitive assays like real-time polymerase chain reaction (RT-PCR), DNA microarray,
61 and loop-mediated isothermal amplification (LAMP). These technologies determine the mutations
62 in the genes to identify drug resistance. In some populations of HIV-infected presumptive TB

63 patients, the lateral flow lipoarabinomannan assay (LF-LAM) test is advised to aid in the diagnosis
64 of TB (6).

65 The invention of the Xpert® MTB/RIF Assay (Cepheid, USA), which simultaneously detects the
66 presence of *Mycobacterium tuberculosis* (MTB) and rifampicin resistance, has transformed the
67 diagnosis of TB. Rifampicin inhibits DNA-directed RNA synthesis of MTB proteins by binding to
68 the subunit of the bacterial DNA-dependent RNA polymerase (*rpoB*) enzyme. Rifampicin
69 resistance has been associated with the *rpoB* gene mutation. Almost 96.1% of rifampicin-resistant
70 MTB strains have *rpoB* mutations (7). The rifampicin resistance is the proxy sign of the MDR-TB
71 (8,9). GeneXpert/MTB RIF is a cartridge-based, automated hemi-nested-nested real-time
72 Polymerase Chain Reaction (PCR) system that utilizes five overlapping probes named Probe A
73 (codons 507–511), Probe B (codons 511–518), Probe C (codons 518–523), Probe D (codons 523–
74 529) and Probe E (codons 529–533) (10).

75 Studies in Africa revealed that the commonest mutation of *rpoB* occurs at probes E and D (11–13).
76 However, the literature shows different pattern distributions of the *rpoB* gene mutation of MTB
77 associated with drug resistance (11–13). There is a need to determine whether the findings in other
78 studies apply to our setting due to the varied findings obtained in various geographical areas. No
79 other study has been conducted in Tanzania to reveal the patterns of *rpoB* mutation. Due to efforts
80 to increase access to GeneXpert MTB/RIF diagnosis in the country, there is also a need to determine
81 the factors associated with Rifampicin-resistant TB.

82 **Methods**

83 **Study design and setting**

84 We conducted a retrospective cross-sectional study involving the Tanzania National Tuberculosis
85 and Leprosy Program (NTLP) data collected from January 2020 through December 2022. The study
86 covered Presumptive TB cases notified to NTLP from 26 regions of Tanzania's mainland. The
87 NTLP is tasked with preventing tuberculosis and leprosy as serious public health concerns in
88 Tanzania, and it was launched in 1977 as a single combined programme for the two diseases.

89 **Data collection**

90 We extracted demographic and clinical data from eTL and laboratory results from gxalert databases
91 on 10th October, 2023 and then exported them to Microsoft Excel. The demographic data from the
92 eTL register and laboratory results data were linked between these two databases. The identifiers
93 used to link the two databases were patient name, health facilities, district, and year. The variables
94 of interest from the two databases were demographic characteristics (age, gender, residence),
95 clinical characteristics (TB treatment history, type of TB, bacillary load, HIV status), and geneXpert
96 results.

97 **Data analysis**

98 We presented the descriptive analysis with frequency distributions (%) for categorical variables and
99 a mean was a measure of central tendency for age. Regression analyses (bivariate and multivariate)
100 were performed to assess the relationship between demographic and clinical characteristics as
101 independent variables and the rifampicin resistance as an outcome variable. Factors with a p-value
102 of 0.20 in the bivariate analyses were included in the multivariable model using forward selection.
103 The 95% confidence interval (CI) was presented, and a significance level of $p < 0.05$ was used.

104 **Results**

105 We extracted data for 112,768 nonrepeating patients tested for TB using GeneXpert. Of all, 56,662
106 (50.2%) had laboratory-confirmed TB. Rifampicin resistance was identified in 450/56,662 (0.8%)
107 patients with MTB. The specific gene mutations in the rpoB gene of *Mycobacterium tuberculosis*
108 were identified in the form of the missing probes, which indicated a specific mutation occurs at a
109 specific codon in the rpoB gene named Probe A (codons 507–511), Probe B (codons 511–518),
110 Probe C (codons 518–523), Probe D (codons 523–529), and Probe E (codons 529–533). Missing
111 probes (specific rpoB mutation detected) were found in 219/ 450 (48.7%) samples with Rifampicin-
112 resistant MTB, and no missing probes (no specific rpoB mutation detected) in 231/450 (51.3%)
113 with Rifampicin-resistant. Rif Indeterminate were observed in 658/56,662 (1.16%) of patients with
114 MTB and were excluded in further analysis (Fig 1).

115

116 **Fig 1. Flow chart of participants' analysis**

117 **Demographic and clinical characteristics of study participants**

118 A total of 56,004 participants had clear status of MTB and rifampicin resistance. Most of them,
119 38,705/56,004 (69.11%) were male. The age group 35- 44 years accounted for the largest cases,
120 13,512/56,004 (24.13%). Most participants, 55,192/56,004 (98.55%), had pulmonary TB.
121 Participants with new TB were 53,818/56,004 (96.1%), and 45,016/56,004 (80.38%) were HIV-
122 negative (Table 1). The Dar es Salaam region contributed 10,524/56,004 (18.79%) cases, which is
123 higher than in any other region. The lowest number of cases were reported from the Katavi region.
124 The regional distribution of cases is shown in Fig 2.

125 **Table 1. Participants' demographic and clinical characteristics (N=56,004)**

Variable	Frequency	Percent (%)
Age Group (years)		
<15	1765	3.15

Variable	Frequency	Percent (%)
15-24	6441	11.5
25-34	12637	22.56
35-44	13512	24.13
45-54	10460	18.68
>55	11189	19.98
Mean age (SD)	41(16.4)	
Gender		
Male	38705	69.11
Female	17299	30.89
TB Type		
Pulmonary	55192	98.55
Extra pulmonary	550	0.98
Pulmonary and extra pulmonary	262	0.47
Treatment History		
New patient	53818	96.1
Previous treated	2186	3.9
HIV status		
Positive	10601	18.93
Negative	45016	80.38
Unknown	387	0.69

126

127 **Fig 2. Map showing the proportion distribution of study participants per region**

128 **Pattern of specific rpoB gene mutations in MTB**

129 Specific mutations (missing probe) were detected in 219/450 (48.7%) rifampicin-resistant TB. The
130 most prevalent mutation, 89/219 (40.64%), occurred at Probe E, followed by Probe D, 44/219
131 (20.09%), and the least mutation, 10/219 (4.56%), occurred at Probe C. We found a mutation
132 combination of Probe A and B, 5/219 (2.28%), Probe A and D, 2/219 (0.91%), Probe A and E 1/219
133 (0.46%), and Probe B and E 1/219 (0.46%). One patient had a triple mutation combination at Probe
134 A, D, and E 1/219 (0.46%) (Table 2).

135 **Table 2. Frequency and distribution of specific rpoB gene mutations (N=219)**

Probes	#Codons	Frequency	Percent (%)
Probe A	507–511	21	9.59
Probe B	511–518	39	17.81
Probe C	518–523	10	4.57
Probe D	523–529	44	20.09
Probe E	529–533	89	40.64
Probe A+B		5	2.28
Probe A+D		2	0.91
Probe A+E		1	0.46
Probe B+E		1	0.46
Probe A+D+E		1	0.46

136

137 **The proportion of participants with no missing probe**

138 Specific rpoB mutation were not detected (no missing probe) in 231/450 (51.3%) participants with
 139 Rifampicin-resistance. We found that no missing probes were significantly higher in new TB
 140 patients, 189/334 (56.59%) compared to previously treated patients, 42/116(36.21%) (p = 0.003).
 141 Patients with a very low TB bacillary load, 199/263 (75.67%), had a higher number of no missing
 142 probes when compared with other categories (p<0.001). There was no statistically significant
 143 difference of no missing probes for other variables (Table 3).

144 **Table 3. Demographic and Clinical characteristics of the number of no-missing probe study**
 145 **participants (N=450)**

Variable	Total Rifampicin Resistant	# No missing probe	Proportion	P value
Age Group				
<15	6	3	50.00	
15-59	376	185	49.20	
>59	68	43	63.24	0.103
Gender				

Variable	Total Rifampicin Resistant	# No missing probe	Proportion	P value
Male	312	168	53.85	0.133
Female	138	63	45.65	
TB Type				0.59
Pulmonary	438	224	51.14	
Extra pulmonary	5	2	40.00	
Pulmonary and extra pulmonary	7	5	71.43	
Treatment History				0.003
New patient	334	189	56.59	
Previous treated	116	42	36.21	
HIV status				0.12
Positive	134	59	44.03	
Negative	306	167	54.58	
Bacillary Load				<0.001
High	61	10	16.39	
Medium	66	5	7.58	
Low	60	17	28.33	
Very low	263	199	75.67	

146

147 **Rifampicin resistance and participant characteristics**

148 GeneXpert detects the mutation in the rpoB mutations, and the final results are provided as
 149 rifampicin-resistant. The rpoB gene mutation was higher in 15-59-year-old patients, 383/45,782
 150 (0.84%) compared to other age groups (p = 0.047). More mutations were found in patients with
 151 pulmonary and extra-pulmonary TB patients (7/262, 2.67%) than in pulmonary or extra-pulmonary
 152 alone (p = 0.003). Furthermore, we found that previously treated patients had a higher mutation
 153 rate, 116/2186 (5.31%), compared to new patients (p<0.001). HIV-positive TB patients had a higher
 154 gene mutation, 134/10601 (1.26%), than HIV-negative, 306/45016(0.68%) (p<0.001). Other
 155 variables like gender and point of health service showed no significant difference in gene mutation
 156 (Table 4).

157

158 **Table 4. Distribution of rifampicin resistance and participants' characteristics (N=56,004)**

Variable	Total participants	# Total RR	Proportion	P value
Age Group				
<15	1765	6	0.34	
15-59	45782	383	0.84	
>59	8457	61	0.72	0.047
Gender				
Male	38705	312	0.81	
Female	17299	138	0.80	0.918
TB Type				
Pulmonary	55192	438	0.79	
Extra pulmonary	550	5	0.91	
Pulmonary and extra pulmonary	262	7	2.67	0.003
Treatment History				
New patient	53818	334	0.62	
Previous treated	2186	116	5.31	<0.001
HIV status				
Positive	10601	134	1.26	
Negative	45016	306	0.68	<0.001
Referral type				
Community	46897	364	0.78	
Health facility	6167	60	0.97	
Others	2940	26	0.88	0.234

159 ** The frequency for HIV status is less due to unknown status.

160 **Predictors of rifampicin resistance**

161 Compared to pulmonary TB, patients with both pulmonary and extra-pulmonary TB had about four
 162 times greater odds of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 – 8.32). The
 163 likelihood of rifampicin resistance was nearly nine times higher in previously treated patients
 164 compared to new (AOR 8.66, 95%CI: 6.97 – 10.76). HIV-positive individuals had nearly twice the
 165 odds of developing rifampicin resistance than HIV-negative individuals (AOR 1.91, 95%CI: 1.51
 166 – 2.42) (Table 5).

167 **Table 5. Multivariate Logistic regression analysis for the predictors of Rifampicin resistance**

Characteristic	Rif. resistance n (%)	COR (95% CI)	P-value	AOR (95% CI)	P- value
Age Group					
<15	6 (0.34)	Ref		Ref	
15-59	383 (0.84)	2.47 (1.10 – 5.55)	0.028	2.07 (0.92 – 4.67)	0.078
>59	61 (0.72)	2.13 (0.92 – 4.93)	0.078	1.95 (0.84 – 4.54)	0.119
TB Type					
Pulmonary	438 (0.79)	Ref		Ref	
Extra pulmonary	5 (0.91)	1.15 (0.47 – 2.78)	0.762	1.19 (0.49 – 2.92)	0.694
Pulmonary and extra pulmonary	7 (2.67)	3.43 (1.61 -7.31)	0.001	3.88 (1.80 – 8.32)	0.001
Treatment History					
New patient	334 (0.62)	Ref		Ref	
Previous treated	116 (5.31)	8.97 (7.23 – 11.13)	<0.001	8.66 (6.97 – 10.76)	<0.001
HIV status					
Negative	306 (1.26)	Ref		Ref	
Positive	134 (0.68)	1.87 (1.53 – 2.29)	<0.001	1.82 (1.44 – 2.30)	<0.001
Referral type					
Community	364 (0.78)	Ref		Ref	
Health facility	60 (0.97)	1.25 (0.95 – 1.65)	0.104	0.83 (0.61 – 1.14)	0.250
Others	26 (0.88)	1.14 (0.76 – 1.70)	0.519	0.99 (0.66 – 1.48)	0.969

168

169 Discussion

170 The current study found that the most prevalent mutation in rpoB gene mutation in MTB was at
 171 probe E codon (529–533) (40.64%), followed by Probe D codon (523–529) 20.09% which was
 172 similar to studies done in Nigeria, Uganda, Pakistan, Addis Ababa Ethiopia, and Bangladesh (13–
 173 17), the similarities suggests that a significant number of low-income individuals migrating for
 174 shelters may be responsible for the spread of mutant strains within the community (18). Our findings
 175 differed from the study done in Northeast India and Enugu, South Eastern Nigeria, which revealed
 176 that the most prevalent mutations were detected at probes A and D, respectively (19,20). The
 177 differences might be attributed to geographical differences caused by the variations in the *M.*

178 *tuberculosis* lineage (21). According to the results of our study and previous studies, probe E is
179 linked to the most common probe mutation in the *rpoB* gene mutation.

180 The study found that new TB patients had a significantly higher number of specific *rpoB* mutations
181 not detected among those with rifampicin resistance than previously treated patients. Our finding is
182 similar to a Northeast India study (20). This may result from an early stage of TB diagnosis, which
183 may have a low bacillary load. No missing probe may also be triggered by various probes having
184 varying target hybridization dynamics, which might have a higher impact after extended PCR cycles
185 (22). Patients with low TB bacillary load also had more no-missing probes. This could mean
186 GeneXpert testing in patients with less advanced disease and lower bacterial density (new patients)
187 is considered less accurate in detecting rifampicin-resistant tuberculosis (23). The very low bacillary
188 load on GeneXpert testing was shown to be substantially linked to false rifampicin resistance during
189 the initial GeneXpert assay (22). The samples with very low bacillary load were not retested; hence,
190 the rate of false positives for rifampicin resistance could not be determined.

191 The rifampicin resistance was found more in patients with both pulmonary and extra-pulmonary
192 TB than in pulmonary or extra-pulmonary alone. In addition, patients with both pulmonary and
193 extra-pulmonary TB had almost four times greater odds of developing rifampicin resistance. Our
194 findings were comparable to the study done in the Debre Markos Referral Hospital Ethiopia (24).
195 We also found that previously treated patients had significantly higher rifampicin resistance than
196 new patients. The likelihood of rifampicin resistance was nearly nine times higher in previously
197 treated patients than in new patients, similar to the study done in Nepal (25). Our findings support
198 that MTB increases the ability to develop resistance when exposed to anti-TB drugs, especially in
199 patients with poor adherence to treatment (26). In our study, the odds of developing rifampicin

200 resistance in previously treated patients were higher than in Somalia and other East Gojjam zone
201 northwest Ethiopia studies, which revealed four and six times, respectively (27,28).

202 HIV-positive TB patients had a higher gene mutation than HIV-negative. HIV-positive individuals
203 had nearly twice the odds of developing rifampicin resistance than HIV-negative individuals; this
204 was similar to the studies done in northwest Ethiopia (27,29). Variations in TB/HIV co-infection
205 have been reported in several studies, indicating challenges in diagnosis and treatment due to
206 unusual clinical presentations and difficulties in diagnosis and treatment (30–32). This may be due
207 to differences in TB control strategies and approaches (29). More rifampicin-resistant MTB in HIV
208 patients might be caused by poor treatment adherence. Poor adherence to treatment is the primary
209 factor contributing to drug resistance (25,31). This highlights the need for more surveillance and
210 community involvement.

211 The study had limitations, including missing variables and being unable to confirm false positive
212 rates for rifampicin resistance at low bacillary load. However, the large sample size of participants
213 from all Tanzania mainland regions made the findings representative and generalisable to all
214 regions.

215 **Conclusion**

216 The rate of rifampicin resistance in our study was low compared to other studies done in Tanzania.
217 The Probe E (codons 529–533)-related mutations were the most prevalent *rpoB* gene mutation.
218 Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-TB are
219 associated with rifampicin resistance. The findings highlight the need to strengthen the surveillance
220 of MDR-TB among patients identified with a higher risk of rifampicin resistance.

221 **Ethical considerations**

222 Ethical approval was obtained from the MUHAS Senate Research and Publications Committee of
223 Muhimbili University of Health and Allied Sciences, Ref. No. DA.282/298/01L/629. Approval to
224 use the national TB program data was obtained from the NTLP Program Manager in the Ministry
225 of Health (MoH). The data was routinely collected by health facilities providing TB care and
226 treatment services in which ethical issues are strongly advocated.

227 **Author contributions**

228 PRT, AJ, HK, MVM and LU authors contributed equally to the design. PRT, MRM, MCM, SSN,
229 RMK, CF, RB, PS and JK did data collection and write-up of this manuscript. AJ and MVM
230 reviewed the manuscript. All authors read and approved the final manuscript.

231 **Acknowledgments**

232 We are very grateful to the Muhimbili University of Health and Allied Sciences, Ministry of Health,
233 NTLP program, Tanzania Field Epidemiology and Laboratory program for technical support of this
234 study.

235 **References**

- 236 1. Global Tuberculosis report 2022. 2022. Available from: <http://apps.who.int/bookorders..>
- 237 2. Yan Shao, Dandan Yang, Weiguo Xu, Wei Lu, Honghuan Song, Yaoyao Dai, Hongbing
238 Shen & Jianming Wang. Epidemiology of anti-tuberculosis drug resistance in a chinese
239 population: Current situation and challenges ahead. BMC Public Health. 2011;11.
240 <https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-110#Abs1>


- 241 3. Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East
242 Africa: A systematic review and meta-analysis. PLoS One. 2022 Jun 1;17(6 June). [https://doi: 10.1371/journal.pone.0270272](https://doi:10.1371/journal.pone.0270272).
- 243
- 244 4. Tuberculosis: Multidrug-resistant tuberculosis (MDR-TB). [https://www.who.int/news-](https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb))
245 [room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-\(mdr-tb\)](https://www.who.int/news-room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb))
- 246 5. World Health Organization. The End Strategy TB. End TB Strateg. 2015;53(9):1689–99.
247 <https://www.who.int/publications-detail-redirect/WHO-HTM-TB-2015.19>
- 248 6. World Health Organization (WHO). WHO operational handbook on tuberculosis. Module 3:
249 Diagnosis - Rapid diagnostics for tuberculosis detection 2021 update
250 <https://apps.who.int/iris/bitstream/handle/10665/340256/9789240022614-eng.pdf>
- 251 7. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of
252 Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient
253 technology. J Clin Microbiol. 2010;48(1):229–37. [https://doi: 10.1128/JCM.01463-09](https://doi:10.1128/JCM.01463-09). Epub
254 [2009 Oct 28](https://doi:10.1128/JCM.01463-09).
- 255 8. Unit MR, Health P, Hospital D, Grove ED. The rapid diagnosis of isoniazid and rifampicin
256 resistance in. 1998;47:189–96. J Med Microbiol. 1998 Mar;47(3):189-96.
257 <https://doi:10.1099/00222615-47-3-189>.
- 258 9. Tao N. Risk factors for drug- - resistant tuberculosis , the association between resistant
259 comorbidity status and drug- - patterns: a retrospective study of previously treated
260 pulmonary tuberculosis in Shandong , China , during 2004 – 2019. 2021;1–9. [http://doi:](http://doi:10.1136/bmjopen-2020-044349)
261 [10.1136/bmjopen-2020-044349](http://doi:10.1136/bmjopen-2020-044349).

- 262 10. Akalu GT, Tessema B, Petros B. High proportion of RR-TB and mutations conferring RR
263 outside of the RRDR of the rpoB gene detected in GeneXpert MTB/RIF assay positive
264 pulmonary tuberculosis cases, in Addis Ababa, Ethiopia. PLoS One. 2022;17(12
265 December):1–18. <http://dx.doi.org/10.1371/journal.pone.0277145>
- 266 11. Reta MA, Alemnew B, Abate BB, Fourie PB. Prevalence of drug resistance-conferring
267 mutations associated with isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in
268 Ethiopia: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2021;26:207–
269 18. <https://doi.org/10.1016/j.jgar.2021.06.009>
- 270 12. Lavu EK, Johnson K, Banamu J, Pandey S, Carter R, Coulter C, et al. Drug-resistant
271 tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–
272 2017 . Public Heal Action. 2019;9(1):S12–8. <https://doi:10.5588/pha.19.0005>.
- 273 13. Mboowa G, Namaganda C, Ssenooba W. Rifampicin resistance mutations in the 81 bp
274 RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF
275 in Kampala, Uganda: A retrospective study. BMC Infect Dis. 2014 Sep 4;14(1):1–5.
276 <https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-481>
- 277 14. Ullah I, Shah AA, Basit A, Ali M, khan A, Ullah U, et al. Rifampicin resistance mutations in
278 the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert
279 MTB/RIF in Khyber Pakhtunkhwa, Pakistan: A retrospective study. BMC Infect Dis.
280 2016;16(1):4–9. <http://dx.doi.org/10.1186/s12879-016-1745-2>
- 281 15. Alemu A, Tadesse M, Seid G, Mollalign H, Eshetu K, Sinshaw W, et al. Does Xpert®
282 MTB/RIF assay give rifampicin resistance results without identified mutation? Review of
283 cases from Addis Ababa, Ethiopia. BMC Infect Dis. 2020;20(1):1–6. <https://doi:>


- 284 [10.1186/s12879-020-4817-2](https://doi.org/10.1186/s12879-020-4817-2)
- 285 16. Uddin MKM, Rahman A, Ather MF, Ahmed T, Rahman SMM, Ahmed S, et al. Distribution
286 and frequency of rpoB mutations detected by xpert MTB/RIF assay among beijing and non-
287 beijing rifampicin resistant Mycobacterium tuberculosis isolates in Bangladesh. Infect Drug
288 Resist. 2020;13:789–97. <https://www.dovepress.com/infection-and-drug-resistance-journal>
- 289 17. Ochang EA, Udoh UA, Emanghe UE, Tiku GO, Offor JB, Odo M, et al. Evaluation of
290 rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene
291 mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State,
292 Nigeria. Int J Mycobacteriology. 2016;5:S145–6.
293 <http://dx.doi.org/10.1016/j.ijmyco.2016.09.007>
- 294 18. Adhikari S, Saud B, Sunar S, Ghimire S, Yadav BP. Status of rpoB gene mutation associated
295 with rifampicin-resistant Mycobacterium tuberculosis isolated in a rural setting in Nepal.
296 Access Microbiol. 2021;3(3):10–3. <https://DOI: 10.1099/acmi.0.000202>
- 297 19. Ugwu KO, Onah IS, Mbah GC, Ezeonu IM. Rifampicin resistance patterns and dynamics of
298 tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria. J Infect Dev
299 Ctries. 2020;14(9):1011–8. <https://doi:10.3855/jidc.12736>.
- 300 20. Sailo CV, Lalremruata R, Sanga Z, Fela V, Kharkongor F, Chhakchhuak Z, et al. Distribution
301 and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected
302 by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: J
303 Clin Tuberc Other Mycobact Dis. <https://doi.org/10.1016/j.jctube.2022.100342>
- 304 21. Ektefaie Y, Dixit A, Freschi L, Farhat MR. Globally diverse Mycobacterium tuberculosis
305 resistance acquisition: a retrospective geographical and temporal analysis of whole genome

- 306 sequences. *The Lancet Microbe*. 2021;2(3):e96–104. [http://dx.doi.org/10.1016/S2666-](http://dx.doi.org/10.1016/S2666-5247(20)30195-6)
307 [5247\(20\)30195-6](http://dx.doi.org/10.1016/S2666-5247(20)30195-6)
- 308 22. Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, et al.
309 Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a
310 prospective observational study in Rwanda. *The Lancet Microbe* [Internet]. 2020;1(2):e74–
311 83. [http://dx.doi.org/10.1016/S2666-5247\(20\)30007-0](http://dx.doi.org/10.1016/S2666-5247(20)30007-0)
- 312 23. Variava E, Moloantoa T, Martinson NA. Discrepancies in Xpert tuberculosis testing. *The*
313 *Lancet Microbe* [Internet]. 2020 Jun 1 [cited 2023 Nov 30];1(2):e47–8.
314 <http://www.thelancet.com/article/S2666524720300331/fulltext>
- 315 24. Mulu W, Abera B, Yimer M, Hailu T, Ayele H, Abate D. Rifampicin-resistance pattern of
316 *Mycobacterium tuberculosis* and associated factors among presumptive tuberculosis patients
317 referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. *BMC Res*
318 *Notes*. 2017;10(1):1–8. <https://doi.org/10.1186/s12879-019-3943-1>
- 319 25. Sah SK, Bhattarai PR, Shrestha A, Dhami D, Guruwacharya D, Shrestha R. Rifampicin-
320 resistant mycobacterium tuberculosis by genexpert mtb/rif and associated factors among
321 presumptive pulmonary tuberculosis patients in nepal. *Infect Drug Resist*. 2020;13:2911–9.
322 <https://www.dovepress.com/infection-and-drug-resistance-journal>
- 323 26. Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in Sub-
324 Saharan Africa: how strongly associated with previous treatment and HIV co-infection?
325 *Ethiop J Health Sci*. 2013;23(3):271–82. <https://doi:10.4314/ejhs.v23i3.10>.
- 326 27. Adane K, Ameni G, Bekele S, Abebe M, Aseffa A. Prevalence and drug resistance profile of
327 *Mycobacterium tuberculosis* isolated from pulmonary tuberculosis patients attending two

- 328 public hospitals in East Gojjam zone, northwest Ethiopia Infectious Disease epidemiology.
329 BMC Public Health. 2015;15(1):1–8. <https://doi:10.1186/s12889-015-1933-9>
- 330 28. Ali MM, Weldegebreal F, Kabew G, Urgesa K. Rifampicin resistant Mycobacterium
331 tuberculosis and associated factors among presumptive pulmonary tuberculosis patients in
332 Mogadishu, Somalia. SAGE Open Med. 2023;11. <https://doi:10.1177/20503121221148603>
- 333 29. Ayalew ML, Yigzaw WB, Tigabu A, Tarekegn BG. Prevalence, associated risk factors
334 rifampicin resistance pattern of pulmonary tuberculosis among children at debre markos
335 referral hospital, Northwest, Ethiopia. Infect Drug Resist. 2020;13:3863–72.
336 <https://DOI:10.2147/IDR.S277222>
- 337 30. Yitayew YA, Bekele DM, Wondimeneh B, Menji DZA. Mother to child transmission of HIV
338 and associated factors among HIV exposed infants at public health facilities, Dessie town,
339 Ethiopia. HIV/AIDS - Res Palliat Care. 2019;11:343–50. <https://doi:10.2147/HIV.S221409>
- 340 31. Diriba K, Awulachew E, Churiso G. The magnitude of mtb and rifampicin resistance mtb
341 using xpert-mtb/rif assay among tuberculosis suspected patients in gedeo zone, southern
342 ethiopia. Infect Drug Resist. 2021;14:3961–9.
343 <https://doi:10.2147/IDR.S327607.eCollection2021>
- 344 32. Jaganath D, Zalwango S, Okware B, Nsereko M, Kisingo H, Malone LS, et al. Contact
345 investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis.
346 2013;57(12):1685–92. <https://doi:10.1093/cid/cit645>



Figure



Figure